Psychotherapist, Pierre Bouchard talks with our Director of Content, Jill Ettinger.
Similar Posts
Albert Labs: “The First to Market” Using Psychedelics to Treat Anxiety in Cancer Patients
In this interview, David Flores sits down with Dr. Mike…
Will MindMed Partner With Johnson & Johnson for 18MC? ( MNMD & J&J In the Speculation Zone)
What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.
MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.
MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #MNMD
The Top 5 Psychedelics Podcasts
New psychedelic podcasts are popping up every week, but which ones are worth listening to? Here’s a few of our favorites.
Examining Ketamine Therapy with Myriam Barthes, Journey Clinical
In today’s episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine therapy compares to other psychedelic-assisted therapies.
How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
Top 5 PSYCHEDELIC STOCKS to buy in 2021 (MMEDF, NUMI, RVV, FTRP, CMPS🔥)
We hope that YOU, the psychedelic investor, were able to gain some value from this! 🧠📈 Feel free to drop a comment! 💬 Also, you can support the channel by liking the video and checking out the links below.👇🏼 Appreciate you. 🙏🏼
There’s a SHROOM BOOM on its way. Psychedelic companies are IPOing left and right and along with them are the top 5 psychedelic stocks to buy in 2020! On this list we got:
Revive Therapeutics (RVV), Numinus (NUMI), Field Trip (FTRP), Compass Pathways (CMPS), and last but not least…MinDMed (MMEDF).
Beat by: Prod. Riddiman
Stream beats on:
Spotify: https://spoti.fi/2u4ZS7R
Apple Music: https://apple.co/2GIxb8j
Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.